Comparingthe ratios of TNF-α and IL-6 secretion by macrophages, the immunemodulation achieved by our ZnO2@CeMOF/Br nanocatalystsis elevated (see also Table ) yet not overly high,, which could yield adverseeffects such as rheumatoid arthritis, atherosclerosis, autoimmune diseases, or metabolic disorders. The gene discussed is IL6; the disease is Other metabolic disease.